Atlas Trials

wang shusen

6 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch wang shusen

RecordFirmDate
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy (NCT05978648)wang shusen2023-09-20
Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer (NCT05656131)wang shusen2022-11-23
Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor. (NCT05411380)wang shusen2022-10-03
Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial (NCT05390476)wang shusen2022-08-01

Track wang shusen automatically

Every clearance here is in the API, with alerts when new ones post.